Drugs /

triptolide analog

Back to Drugs List

Overview

NCI Definition [1]:
A water soluble analog of the diterpenoid triepoxide triptolide isolated from the Chinese herb Tripterygium wilfordii Hook.f., with potential antineoplastic activity. Upon intravenous administration, the triptolide analog inhibits heat shock protein 70 (HSP70) and prevents HSP70-mediated inhibition of apoptosis. This leads to both the induction of apoptosis and a reduction of cancer cell growth. HSP70, a molecular chaperone upregulated in various cancer cells, plays a key role in the inhibition of caspase-dependent and -independent apoptosis.

Clinical Trials

View Clinical Trials for triptolide analog

Triptolide analog has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating triptolide analog, 2 are phase 1 (2 open) and 1 is phase 2 (1 open).

Breast carcinoma, gastric carcinoma, and malignant solid tumor are the most common diseases being investigated in triptolide analog clinical trials [2].

Drug Details

Synonyms [2]:
14-o-phosphonooxymethyltriptolide, triptolide analogue, minnelide, minnelide
Drug Target(s) [2]:
HSPA12A, HSPA14, HSPA1A, HSPA1L, HSPA2, HSPA5, HSPA6, HSPA7, HSPA8, HSPA9
NCIT ID [1]:
C111762

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.